HC Wainwright Has Negative Outlook of Clene FY2028 Earnings

Clene Inc. (NASDAQ:CLNN) – Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Clene in a report issued on Monday, March 24th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $5.26 for the year, down from their prior forecast of $5.53. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share.

Separately, D. Boral Capital restated a “buy” rating and set a $23.00 target price on shares of Clene in a research note on Monday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $55.25.

Clene Trading Down 5.3 %

CLNN opened at $3.92 on Tuesday. Clene has a 12-month low of $3.82 and a 12-month high of $9.20. The company’s 50 day moving average is $4.55 and its 200 day moving average is $4.91. The company has a market cap of $32.64 million, a price-to-earnings ratio of -0.74 and a beta of 0.27.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Monday, March 24th. The company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million.

Institutional Trading of Clene

A number of large investors have recently made changes to their positions in the business. Fullcircle Wealth LLC purchased a new stake in Clene during the fourth quarter valued at approximately $69,000. SBI Securities Co. Ltd. bought a new position in shares of Clene during the 4th quarter valued at approximately $69,000. Renaissance Technologies LLC purchased a new stake in Clene during the 4th quarter valued at $96,000. Geode Capital Management LLC lifted its position in Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after buying an additional 22,539 shares during the last quarter. Finally, Parsons Capital Management Inc. RI purchased a new position in Clene during the fourth quarter worth $194,000. 23.28% of the stock is currently owned by institutional investors.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.